Collegium Pharmaceutical (NASDAQ:COLL) Receives “Neutral” Rating from Piper Sandler

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “neutral” rating restated by equities research analysts at Piper Sandler in a report released on Friday, Benzinga reports. They currently have a $37.00 price target on the specialty pharmaceutical company’s stock, down from their previous price target of $39.00. Piper Sandler’s target price would suggest a potential upside of 4.96% from the company’s previous close.

Several other research analysts have also recently issued reports on COLL. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Jefferies Financial Group upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and increased their price objective for the stock from $41.00 to $44.00 in a research report on Friday, June 7th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday. Finally, HC Wainwright upgraded Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Tuesday, July 30th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock traded down $0.07 during trading hours on Friday, hitting $35.25. The stock had a trading volume of 59,890 shares, compared to its average volume of 468,716. The firm has a market capitalization of $1.15 billion, a PE ratio of 14.49 and a beta of 0.93. Collegium Pharmaceutical has a twelve month low of $20.95 and a twelve month high of $40.95. The stock’s 50 day moving average is $32.99 and its 200 day moving average is $34.81. The company has a debt-to-equity ratio of 1.98, a current ratio of 1.21 and a quick ratio of 1.14.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The firm had revenue of $144.92 million during the quarter, compared to analyst estimates of $147.04 million. As a group, research analysts forecast that Collegium Pharmaceutical will post 5.73 earnings per share for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the firm’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $33.98, for a total value of $1,930,301.86. Following the sale, the executive vice president now directly owns 105,902 shares of the company’s stock, valued at approximately $3,598,549.96. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the firm’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $33.98, for a total value of $1,930,301.86. Following the sale, the executive vice president now directly owns 105,902 shares of the company’s stock, valued at approximately $3,598,549.96. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the completion of the sale, the chief financial officer now directly owns 130,845 shares in the company, valued at $4,476,207.45. The disclosure for this sale can be found here. Insiders have sold a total of 105,502 shares of company stock valued at $3,540,796 over the last quarter. Insiders own 3.98% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds have recently modified their holdings of COLL. Assenagon Asset Management S.A. raised its holdings in shares of Collegium Pharmaceutical by 411.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock valued at $11,661,000 after buying an additional 291,286 shares during the period. LSV Asset Management raised its holdings in shares of Collegium Pharmaceutical by 188.7% during the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after buying an additional 248,751 shares during the period. New York State Common Retirement Fund raised its holdings in shares of Collegium Pharmaceutical by 1,475.5% during the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after buying an additional 188,347 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Collegium Pharmaceutical by 8.2% during the 2nd quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock valued at $54,124,000 after buying an additional 128,003 shares during the period. Finally, Federated Hermes Inc. raised its holdings in shares of Collegium Pharmaceutical by 76.0% during the 4th quarter. Federated Hermes Inc. now owns 212,768 shares of the specialty pharmaceutical company’s stock valued at $6,549,000 after buying an additional 91,911 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.